Construction and characterization of recombinant human C9 or C7 linked to single Chain Fv directed to CD25

Maria Raitses Gurevich, Zvi Fishelson*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Complement-dependent cytotoxicity (CDC) is a potent promoter of tumor clearance during monoclonal antibody therapy. Complement activation on antibody-bearing tumor cells results in formation of the membrane attack complex (MAC), which activates cell death. The complement activation cascade that bridges between antibody binding and MAC formation is regulated by complement inhibitors that are over-expressed on tumor cells. In order to bypass those complement regulators, we have designed an immunoconjugate composed of a humanized single chain Fv of an anti-Tac (CD25) monoclonal antibody fused at its C terminus either to complement protein C9 (scFv-C9) or to complement C7 (scFv-C7) and tagged with six histidines at the C terminal end. Recombinant scFv-C9 and scFv-C7 were expressed in 293T cells and purified. Both are shown to efficiently bind to CD25-positive tumor cells. In addition, scFv-C9, but not scFv-C7, increases MAC deposition on the cells and enhances complement-mediated cell death of target CD25-positive cells. Thus, scFv-C9 fusion protein is potentially a novel reagent for application in cancer immunotherapy.

Original languageEnglish
Pages (from-to)400-408
Number of pages9
JournalMolecular Immunology
Volume55
Issue number3-4
DOIs
StatePublished - Oct 2013

Funding

FundersFunder number
United States-Israel Binational Science Foundation
Israel Science Foundation

    Keywords

    • C7
    • C9
    • CD25
    • Complement
    • ScFv

    Fingerprint

    Dive into the research topics of 'Construction and characterization of recombinant human C9 or C7 linked to single Chain Fv directed to CD25'. Together they form a unique fingerprint.

    Cite this